pharmaphorum

JANUARY 13, 2023

The ‘big three’ insulin producers Novo Nordisk, Eli Lilly, and Sanofi are being sued by the state of California for allegedly working together to set artificially inflated prices for their products. The suit follows legal action over insulin pricing taken by other states, including Arkansas , Kansas, Mississippi, and Minnesota.

Insulin 105

Insulin Manufacturing Production Drugs 105

Bio Pharma Dive

AUGUST 16, 2023

The new coupons include some of the most commonly prescribed diabetes drugs from Eli Lilly, Novo Nordisk and Sanofi.

Insulin 130

Insulin Pharmacy Manufacturing Drugs 130

Fierce Pharma

JULY 11, 2024

The FDA has slowed the roll for Novo Nordisk, rejecting its once-a-week insulin icodec for patients with Type 1 and Type 2 diabetes. regulator made "requests related to the manufacturing process and the type 1 diabetes indication," which the company said it does not expect to remedy by the end of this year.

Insulin 82

Insulin Manufacturing Regulation Marketing 82

BioSpace

NOVEMBER 8, 2023

Citing manufacturing concerns and formulary losses, Novo Nordisk will discontinue its long-acting insulin Levemir by the end of next year amid strong pressure from U.S. lawmakers to lower insulin prices.

Insulin 107

Insulin Manufacturing 107

BioSpace

JULY 11, 2024

The FDA’s Complete Response Letter turned down Novo Nordisk’s application for its once-weekly insulin injection for diabetes mellitus, with “requests” related to the manufacturing process and the type 1 diabetes indication.

Insulin 74

Insulin Manufacturing 74

STAT News

JANUARY 20, 2023

In an attempt to tackle the root causes of inflated insulin prices, the state of California filed a lawsuit last week accusing drug manufacturers and pharmacy benefit managers of artificially and illegally jacking up the price of insulin. The sausage-making of how insulin is priced is not for the faint of heart.

Insulin 105

Insulin Pharmacy Manufacturing Drugs 105

STAT News

OCTOBER 6, 2022

The three companies that dominate the global market for insulin have launched various programs to expand the reach of their medicines in dozens of low and middle-income countries — but their efforts remain patchy and equitable access consequently remains out of reach, according to a new analysis.

Insulin 111

Insulin Regulation Manufacturing Medicine 111

BioSpace

DECEMBER 28, 2020

rBIO launched last week with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.

Insulin 98

Insulin Manufacturing Drugs 98

STAT News

APRIL 21, 2023

WASHINGTON — Amid a scramble to assemble a health care policy package in the Senate, a pair of key senators have significantly changed a proposal to cap insulin costs. The new legislation by Senate Diabetes Caucus co-chairs Sens. Jeanne Shaheen (D-N.H.)

Insulin 98

Insulin Packaging Packaging Pharmacy 98

Bio Pharma Dive

SEPTEMBER 20, 2024

The agency brought action against Caremark, Express Scripts and Optum Rx on Friday, and warned that all drug manufacturers “should be on notice” as well.

Insulin 130

Insulin Pharmacy Manufacturing Drugs 130

Drug Channels

SEPTEMBER 15, 2023

Nicole summarizes MMIT’s research on payers’ views of two crucial market changes: (1) the Inflation Reduction Act of 2022’s requirement to cap insulin prices at $35 for Medicare beneficiaries, and (2) manufacturers’ reduction in list prices for certain insulin products.

Insulin 97

Insulin Manufacturing Drugs Research 97

STAT News

MARCH 9, 2023

Now that Eli Lilly is cutting prices on some of its insulin products, Sen. This week, he introduced a bill that would place a $20 cap on all insulin, a move designed to drastically lower costs for millions of Americans. Bernie Sanders (I-Vt.) is seeking to build on that momentum. Continue to STAT+ to read the full story…

Insulin 98

Insulin Production Manufacturing Drugs 98

Pharmaceutical Technology

JULY 11, 2024

The company did not expect to resolve concerns related to manufacturing and the safety profile for type 1 diabetes by the end of the year.

Insulin 130

Insulin Manufacturing 130

STAT News

MARCH 16, 2023

Following the lead of its rivals, Sanofi will cut the price of its most widely prescribed insulin in the U.S. The change comes after Eli Lilly and then Novo Nordisk announced plans this month to reduce list prices for some of their own insulin products by similar amounts. The moves will go into effect on Jan.

Insulin 98

Insulin Manufacturing Production Marketing 98

Pharmaceutical Technology

JULY 12, 2022

VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy of Vertex for T1D. Through the acquisition, Vertex plans to advance its potentially curative VX-880 programmes in T1D.

Gene Therapy 276

Gene Therapy Insulin Manufacturing Clinical Trials 276

XTalks

SEPTEMBER 23, 2020

Being hailed as the world’s shortest and thinnest needle for insulin injection, Droplet Micron has recently been introduced into the pen needle market by HTL (High Tech Lab)-STREFA, Inc. These are important feature innovations for those that depend on insulin injections. The new and innovative needle measures at just 34G x 3.5mm.

Insulin 98

Insulin Marketing Drug Delivery Compliance 98

Pharmaceutical Technology

FEBRUARY 24, 2023

(LAI-287 + semaglutide) overview A fixed dose combination of GLP-1 analogue semaglutide and LAI-287, long-acting basal insulin is under development for the treatment of type 2 diabetes. The drug candidate is administered as an subcutaneous formulation.The combination acts by targeting GLP-1R and insulin receptor.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

STAT News

MARCH 17, 2023

Enjoy, and see you soon … Following the lead of its rivals, Sanofi will cut the price of its most widely prescribed insulin in the U.S. The three companies are the largest manufacturers of insulin and collectively hold a dominant 80% share of the market. Continue to STAT+ to read the full story…

Insulin 98

Insulin Research Drugs Manufacturing 98

BioPharma Reporter

APRIL 17, 2023

The South Korean company is set to create a new facility in West Virginia to house insulin manufacturing and to deliver its insulin products in the country.

Insulin 52

Insulin Manufacturing Production Regulation 52

Pharmaceutical Technology

JUNE 29, 2022

For hundreds of years, we have found myriad uses for microbial enzymes in manufacturing – from food, drink, and household products to a range of industrial applications. The enzymes must be manufactured under cGMP conditions – completely free of animal-derived ingredients.”. Developing best-in-class speciality enzymes.

Drugs 295

Drugs Gene Therapy Production Manufacturing 295

Camargo

OCTOBER 14, 2020

The FDA is planning two listening sessions to allow manufacturers, developers, health care providers, researchers, and other interested parties to learn more about the purpose and function of the DHCoE. Sign up here for the October or November listening sessions.

Development 196

Development Insulin Drug Delivery Production 196

FDA Law Blog

DECEMBER 3, 2023

As part of this change, the Coverage Gap Discount Program (CGDP), a program that has existed since 2011, will sunset on December 31, 2024, and be replaced by the Medicare Part D Manufacturer Discount Program (the “Discount Program”). CMS will send the final manufacturer invoice for discount liabilities accrued by then on April 30, 2028.

Manufacturing 105

Manufacturing Drugs Compliance Pharmacy 105

BioPharma Reporter

JULY 16, 2024

Novo Nordisk will have to fulfill requests from the FDA regarding the manufacturing process and the indication before it can receive approval for insulin icodec.

Insulin 52

Insulin Manufacturing Regulation Marketing 52

Drug Patent Watch

JANUARY 13, 2025

Unlike traditional generic drugs, biosimilars face a more complex regulatory pathway and manufacturing process, which influences their market entry and adoption rates. ” Diabetes: Addressing a Global Epidemic With diabetes affecting millions worldwide, the advent of biosimilar insulins has been particularly impactful.

Marketing 78

Marketing Insulin Generic Drugs Medicine 78

Outsourcing Pharma

JULY 18, 2023

Convatec Group, a medical products and technologies company focused on chronic conditions, has partnered with Tandem Diabetes Care on a new five-inch infusion set for Tandem Mobi, the worldâs smallest durable automated insulin delivery system.

Insulin 80

Insulin Manufacturing Production Regulation 80

pharmaphorum

MARCH 2, 2022

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time. Smart insulin pens are expected to drive the insulin pen market from $13.8

Insulin 52

Insulin Marketing Doctor Doctors 52

XTalks

JANUARY 21, 2025

TriClip G4 System Manufacturer/developer : Abbott Medical Date of FDA approval : April 1, 2024 Approved for : Tricuspid regurgitation (TR). Abbott Spinal Cord Stimulation (SCS) Systems Manufacturer/developer : Abbott Medical Date of FDA approval : May 30, 2024 Approved for : Chronic, hard-to-manage pain in the torso, arms and legs.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

The Pharma Data

AUGUST 17, 2021

approval of pump use for Lilly’s novel insulin is latest development designed to help people with diabetes manage blood sugar levels. Lyumjev, a novel formulation of insulin lispro developed to speed the absorption of insulin into the bloodstream and reduce A1C levels, was approved by the FDA in June 2020.

Insulin 52

Insulin FDA Approval Doctor Doctors 52

XTalks

FEBRUARY 24, 2021

The injection experience is an often-overlooked aspect in insulin administration. For many daily insulin users, the experience is an important one, as it is directly related to quality of life and medication compliance. Related: Droplet Micron Insulin Needle Offers Innovation in Crowded Diabetes Supply Market.

Insulin 64

Insulin Production Drug Delivery Marketing 64

Drug Channels

JANUARY 26, 2021

A new Senate report reveals unprecedented information about PBMs, manufacturers, and the gross-to-net bubble for insulin. Plus, a 2021 update to my all-time favorite chart. P.S. Join the nearly 11,000 followers of my daily links to neat stuff at @DrugChannels on Twitter.

Insulin 52

Insulin Manufacturing Drugs 52

Fierce Pharma

NOVEMBER 8, 2023

While Novo Nordisk struggles with manufacturing concerns and patient coverage on its long-acting insulin Levemir, Bayer missed a primary endpoint in a confirmatory trial for its P13K inhibitor Aliq | While Bayer's P13K Aliqopa couldn't prove its worth in a confirmatory trial, Novo's Levemir faced manufacturing issues and troubles with (..)

Insulin 52

Insulin Manufacturing Marketing Trials 52

Pharmaceutical Technology

DECEMBER 27, 2022

Drug pricing was a hot-button topic, and William Newton found that while e-commerce chains could cut insulin prices , any major change won’t happen overnight. In pharma manufacturing, continuous manufacturing protocols continued to garner interest , but experts told Adam that their use has been gradual.

Clinical Trials 306

Clinical Trials Clinical Trials Trials Vaccine 306

The Pharma Data

SEPTEMBER 30, 2021

Lilly’s Insulin Lispro Injection, 100 units/mL — first introduced at half the list price of branded Humalog® (insulin lispro injection, 100 units/mL) in 2019 — will now have a 70 percent lower list price than Humalog U-100 starting January 1, 2022 Insulin Lispro Injection can be ordered through all U.S.

Insulin 52

Insulin Pharmacy Branding Medicine 52

STAT News

MARCH 9, 2023

WASHINGTON — President Biden made lowering drug prices a key part of his budget with proposals to expand Medicare drug price negotiation, squeeze more rebates out of drug companies, and lower the cost of insulin for everyone with insurance. The request made Thursday also details a $7.2

Cosmetics 98

Cosmetics Drugs Insulin Regulation 98

Pharmaceutical Technology

APRIL 10, 2023

Under the deal, Cipla will be responsible for the manufacturing and marketing of Galvus and its combination brands from 1 January 2026. Furthermore, Galvus can be used in combination with other medicinal products such as insulin when unable to offer adequate glycaemic control.

Branding 130

Branding Drugs Insulin Production 130

pharmaphorum

JANUARY 28, 2021

One of these markets is the insulin market. Up until now, the insulin market has experienced little competition and, as a result, prices have soared over the years. Currently, more than seven million patients rely on insulin, and that number is growing each year. But, that will soon be changing, due to biosimilars.

Marketing 119

Marketing Insulin HR Production 119

XTalks

MARCH 15, 2024

The drugs include Lilly’s newly approved GLP-1 obesity drug Zepbound (tirzepatide), around a dozen of the company’s insulins and migraine drug Emgality (galcanezumab). It is estimated that more than 8 million Americans rely on insulin products to manage their diabetes.

Pharmacy 111

Pharmacy Drugs Insulin Branding 111